Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902915 | 1.00 | TDP1 (0.54) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL1636077 | 0.89 | TDP1 (0.60) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL1424697 | 0.85 | TDP1 (0.56) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL29888274 | 0.85 | TDP1 (0.50) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL29788829 | 0.85 | TDP1 (0.56) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL574038 | 0.85 | TDP1 (0.50) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL27843138 | 0.84 | TSHR (0.50) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL14411817 | 0.83 | TDP1 (0.54) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL7327212 | 0.82 | TDP1 (0.41) | TDP1TSHRSMN1; SMN2ATMALDH1A1 | |
| SCHEMBL397110 | 0.82 | TDP1 (0.52) | TDP1TSHRSMN1; SMN2ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117049938-B | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117049938-A | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| CN-117049938-B | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117049938-B | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2024-04-11 | — | — | US | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117049938-A | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-117049938-A | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1943230-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2007121416-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121416-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121418-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121418-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007036715-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | TDP1 2576/4885TSHR 56/4885SMN1; SMN2 4262/4885 |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, FGFR2, ERBB3 | TDP1 2967/4885TSHR 3085/4885SMN1; SMN2 1517/4885 |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | CHRM1, CHRM2, CHRM5 | TDP1 2127/4885TSHR 67/4885SMN1; SMN2 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.